In 2014 there was a change to the chemotherapy protocol to treat pancreatic cancer. This resulted in the 2014 trial being delayed. Not the company's fault, rather an advance in treatment that had to be incorporated into the trial. Certainly this reason was not explained well to the market at the time. Similar to the Sirtex product, Oncosil treatment will extend your life, hopefully with less of the pain that goes with pancreatic cancer. By now there should be a number of suitable patients who completed the chemo and now are seeing the disease progress. These are the patients that will benefit from Oncosil treatment at this time.
In 2014 there was a change to the chemotherapy protocol to treat...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.010(0.86%) |
Mkt cap ! $21.74M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.17 | $1.14 | $80.47K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2150 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 7380 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |